

CERTIFICATE OF MAILING

I hereby certify that this TRANSMITTAL is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 31st day of July, 2002.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: Wendy A. Frick



24024

PATENT TRADEMARK OFFICE

PT#4



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hazen, et al.

Serial No.: 10/039,753

Filed: January 2, 2002

For: **MYELOPEROXIDASE, A RISK
INDICATOR FOR CARDIOVASCULAR
DISEASE**

Examiner: Not yet assigned

Art Unit: 3736

Attorney Docket No.: 26473/04177

RECEIVED

AUG - 7 2002

TECHNOLOGY CENTER 1600/2000

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith are the following:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. 2 References; and
4. A Return Receipt Postcard.

It is believed that no further fee is required relating to the filing of this Information Disclosure Statement. If this is not the case, the Patent Office is hereby authorized to charge any related fee to Deposit Account No. 03-0172. A duplicate copy of this sheet is attached.


Respectfully submitted,

Date: July 31, 2002

By: Pamela A. Docherty

Pamela A. Docherty, Reg. No. 40,591
(216) 622-8416

RECEIVED
AUG 22 2002
TECH CENTER 1600/2000



COPY OF PAPERS
ORIGINALLY FILED

Page 1 of 1

Subst. Form PTO-1449	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736

U.S. PATENT DOCUMENTS

Initial*	Document No.	Date	Name	Class	Subcl.	Filing Date
AA						
AB						
AC						
AD						

RECEIVED

AUG - 7 2002

TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AE						
AF						
AG						
AH						
AI						

OTHER PRIOR ART

AJ	"Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease" by Zhang, et al., <u>JAMA</u> , Vol. 286, No. 17, November 7, 2001, pp. 2136-2142.
AK	"Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis? Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?" by Steinberg, et al., <u>Circulation</u> , 2002; 105:2107-2111.
AL	
AM	
AN	
AO	
AP	
AQ	
AR	

Examiner:	Date Considered:
-----------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
AUG 22 2002
TECH CENTER 1600/2900